Tretinoin cream labels are not interchangeable. The Retin-A label says Retin-A is indicated for the treatment of acne vulgaris, while the Renova 0.02% label says it is indicated as an adjunctive agent for fine facial wrinkles. This guide keeps each statement with the label that makes it.
Four labels, different scopes
| Label | What it says |
|---|---|
| Retin-A (cream and gel) | Indicated for topical application in the treatment of acne vulgaris. The safety and efficacy of long-term use in the treatment of other disorders have not been established. |
| Obagi tretinoin cream | Directions say the cream should be applied once a day, before retiring, to the skin where acne lesions appear, using enough to cover the entire affected area lightly. |
| Renova (tretinoin cream) 0.02% | Indicated as an adjunctive agent for the mitigation (palliation) of fine facial wrinkles in patients who use comprehensive skin care and sunlight avoidance programs. |
| Tretinoin Cream, USP (Emollient) 0.05% | Indicated as an adjunctive agent for the mitigation (palliation) of fine wrinkles, mottled hyperpigmentation, and tactile roughness of facial skin in patients who use comprehensive skin care and sunlight avoidance programs. |
Each label is for the product it names. None of them is a label for a compounded cream.
What the acne labels add
The Retin-A label lists cream strengths of 0.1%, 0.05% and 0.025% by weight in a hydrophilic cream vehicle. The statements below come from a label that covers cream and gel, and they are not given by strength.
- Timing: therapeutic results should be noticed after 2 to 3 weeks, but more than 6 weeks of therapy may be required before definite beneficial effects are seen.
- Patient instructions: they say that once acne is under control, regular application of Retin-A should continue until the physician instructs otherwise.
- Early weeks: during the early weeks of therapy, an apparent exacerbation of inflammatory lesions may occur. The label says this is due to the action of the medication on deep, previously unseen lesions and should not be considered a reason to discontinue therapy.
- Sunlight: exposure to sunlight, including sunlamps, should be minimized during use. Patients with sunburn should not use the product until fully recovered, because of heightened susceptibility to sunlight.
What the fine wrinkle labels add
The Renova 0.02% label also lists what the product does not do. It says it does not eliminate wrinkles, repair sun-damaged skin, reverse photoaging, or restore more youthful or younger skin. It says it has not demonstrated a mitigating effect on significant signs of chronic sunlight exposure such as coarse or deep wrinkling, tactile roughness, and mottled hyperpigmentation, among others.
The same label says patients should be warned to use sunscreens (minimum SPF of 15) and protective clothing. It says mitigation of fine facial wrinkling may occur gradually over the course of therapy, and that up to 6 months of therapy may be required before the effects are seen.
The Tretinoin Cream, USP (Emollient) 0.05% label has wider wording and its own limits:
- Its effectiveness has not been established in people greater than 50 years of age or in people with moderately to heavily pigmented skin.
- In double-blinded, vehicle-controlled clinical studies, many patients in the vehicle group achieved desired palliative effects on fine wrinkling, mottled hyperpigmentation, and tactile roughness of facial skin with comprehensive skin care and sunlight avoidance programs.
- With discontinuation of therapy, a majority of patients will lose most mitigating effects on fine wrinkles, mottled hyperpigmentation, and tactile roughness of facial skin.
What this does not tell you
The label versions used here were updated in May 2024 (Retin-A), February 2026 (Renova), February 2025 (Obagi) and August 2012 (Tretinoin Cream, USP (Emollient) 0.05%). Current labels may read differently.
Timing statements describe what a label says, not when any person will notice a change. The labels do not say which strength suits a person. A licensed provider decides that.
The FDA page Compounding and the FDA: Questions and Answers says compounded drugs are not FDA-approved, meaning FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed. Nothing in a label for a named product shows the same strength, quality or result for a compounded cream.